Member Info for Lp160606

Thanks Safy,

It is good to see continuity in their approach, even if it is simply documentation.

I would think it would just be a nice coincidence at this stage, however, i wonder if the other validations sped up Beckmans engagement.. who knows..

Also, i would be surprised if the Beckman deal (IF we are successful and rolled out) does not hold an exclusivity agreement, if we add the value initially thought, they will not want competitors anywhere near us.

Still long way to go but it is good to see progression.

Certainly is a how to, and would of been used to support the approval process.

PP - Its the uncertainty that drains me, this doc has provided me with some answers to previously unanswered questions.

For sure PP, but why allude to governing body (FDA) and draw up a 24 page manual name dropping US based lab equipment and agency if you aren't supremely confident on receiving required approval.

I'm not sure. I am thinking this could of been provided as additional supporting documentation? Upon request of the FDA, an assumption of course..

And is why they've provided the use cases of two US based lab equipment it can work with.

Wonder if this was leveraged for Beckman intro.

Best thing i've read out of Genedrive, hands down.

FDA is mentioned 7 times throughout the doc.

Reads as if it was a supporting doc to that territory. Even points to the FDA website through in one case for further support.

'Genedrive Diagnostics Ltd, its authorized distributor(s), and authorized laboratories using the Genedrive 96 SARS-CoV-2
Kit will ensure that any records associated with this EUA are maintained until otherwise notified by FDA. Such records will
be made available to FDA for inspection upon request. '

link hasn't been pulled mate, read the URL you overstretched it on posting. Remove 'the' at the end of the hyperlink and it will take you there.

The kit is intended to be run on the following real time thermocycler platform

- Roche LightCycler
- Applied Biosystems (Thermofisher)

No mention of Beckmans.. i assume this is due to internal approval not being completed before the publishing of this document.

Nice one Jay, thanks for sharing!

Spot on JH.

Cytiva reached out to the Danahar overlay who put them in touch with Beckman.. that is my series of events.

IF they do pull Beckman off, the volumes will be out of this world.

It will all come down to our negotiated margin.

That will be exactly why. It will be that little volume that if released to the market the SP would react negatively.

There is no other logical reason.

When i pressed for clarification on where they were sold i was told that they couldn't say and it was not deemed necessary to release this information to the market.

@ Posh

http://www.genedriveplc.com/investor-relations/covid19.php

Lol selling to an Estonian corner shop hardly worth boasting about.

Europe would of been their focus hence sending thousands, yes thousands of samples to Spain, Italy & Germany.. nip on back to the Vox presentation for confirmation of this. And went on to sell an amount not worthy of an RNS.. given their previous earnings are pitiful anything 50K plus would of been reasonable to expect an RNS.

Pathetic.

The only reason they posted that in there is to save their blushes and prove they aren't missing deadlines.

Speaking the truth isn't deramping.

Even the rampers are realising this is now very much Beckman or bust.

All these amateurish mistakes they have made add up & DBs radio silence speaks volumes.

How is their PR team saying one thing and the company another. Someone is Bull****ing or incompetent.

Can’t wait to sit on David Budds knee and tell him what I want for Christmas.

Cytiva US based manufacturer of our beads.
Beckman US lab system we are to be absolved into

Danahar the us conglomerate spend thousands on lobbying per year.

If we provide value they’ll ensure FDA is achieved, I’m pretty confident on that.

Send your enquiry to this man - D.Budd@genedrive.com

Thanks Safy.

Very informative article actually, appreciate it.

Troy, wanted to say i agree with your analysis of events. I myself am in GDR for the Covid opportunity alone, the remaining revenue generators are too far out in my opinion to impact SP in the near future.

The Beckman or bust comment is based purely on short to mid term SP potential (2-6 months) and purely focused on Covid. I firmly believe failure there will lead to a massive drop back, circa 50p.

But appreciate your reasoned approach rather than the standard 'stop being negative'. Abbot is certainly a blow and massively affects our opp in the states, was surprised to see posters being dismissive of it truth be told.

We are all hanging on for hopefully a game changing RNS, i sincerely hope it is this week for all holders.

Please tell me you knew Cytiva and beckman sit under the same overreaching organisation?

Jesus Christ.

lol let me spell it out to you Lloyd.

I believe beckman will be a success as Cytiva and beckman sit under the same umbrella hence David Budd and co will have minimal involvement in the operations of said partnership.

And so I think it will be a success.